Marshall H. Chin, M.D., M.P.H.
doi : 10.1056/NEJMp2112063
N Engl J Med 2021; 385:1633-1636
Margaret H. Lloyd Sieger, Ph.D., Rebecca Rebbe, Ph.D., M.S.W., and Stephen W. Patrick, M.D., M.P.H.
doi : 10.1056/NEJMp2111378
N Engl J Med 2021; 385:1636-1639
Elizabeth Adler, M.D.
doi : 10.1056/NEJMp2109812
N Engl J Med 2021; 385:1640-1641
Marco Valgimigli, M.D., Ph.D., Enrico Frigoli, M.D., Dik Heg, Ph.D., Jan Tijssen, Ph.D., Peter Jüni, M.D., Pascal Vranckx, M.D., Ph.D., Yukio Ozaki, M.D., Ph.D., Marie-Claude Morice, M.D., Bernard Chevalier, M.D., Yoshinobu Onuma, M.D., Ph.D., Stephan Windecker, M.D., Pim A.L. Tonino, M.D., Marco Roffi, M.D., Maciej Lesiak, M.D., Felix Mahfoud, M.D., Jozef Bartunek, M.D., Ph.D., David Hildick-Smith, M.D., Antonio Colombo, M.D., Goran Stankovi?, M.D., Ph.D., Andrés Iñiguez, M.D., Ph.D., Carl Schultz, M.D., Ph.D., Ran Kornowski, M.D., Paul J.L. Ong, M.D., Ph.D., Mirvat Alasnag, M.D., Ph.D., Alfredo E. Rodriguez, M.D., Ph.D., Aris Moschovitis, M.D., Peep Laanmets, M.D., Michael Donahue, M.D., Sergio Leonardi, M.D., and Pieter C. Smits, M.D., Ph.D. for the MASTER DAPT Investigators*
doi : 10.1056/NEJMoa2108749
N Engl J Med 2021; 385:1643-1655
The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear.
Michael E. Wechsler, M.D., Marcella K. Ruddy, M.D., Ian D. Pavord, M.D., Elliot Israel, M.D., Klaus F. Rabe, M.D., Ph.D., Linda B. Ford, M.D., Jorge F. Maspero, M.D., Raolat M. Abdulai, M.D., Chih-Chi Hu, Ph.D., Renata Martincova, M.D., Andreas Jessel, M.D., Michael C. Nivens, Ph.D., Nikhil Amin, M.D., David M. Weinreich, M.D., George D. Yancopoulos, M.D., Ph.D., and Helene Goulaouic, Ph.D.
doi : 10.1056/NEJMoa2024257
N Engl J Med 2021; 385:1656-1668
Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new monoclonal antibody against the upstream alarmin interleukin-33. The efficacy and safety of itepekimab as monotherapy, as well as in combination with dupilumab, in patients with asthma are unclear.
Christopher E. Brightling, F.Med.Sci., Parameswaran Nair, M.D., Ph.D., David J. Cousins, Ph.D., Renaud Louis, M.D., Ph.D., and Dave Singh, M.D.
doi : 10.1056/NEJMoa2030880
N Engl J Med 2021; 385:1669-1679
Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear.
Sue Pavord, F.R.C.Path., Marie Scully, M.D., Beverley J. Hunt, M.D., William Lester, M.D., Catherine Bagot, M.D., Brian Craven, M.B., B.Ch., Alex Rampotas, M.R.C.P., Gareth Ambler, Ph.D., and Mike Makris, M.D.
doi : 10.1056/NEJMoa2109908
N Engl J Med 2021; 385:1680-1689
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a new syndrome associated with the ChAdOx1 nCoV-19 adenoviral vector vaccine against severe acute respiratory syndrome coronavirus 2. Data are lacking on the clinical features of and the prognostic criteria for this disorder.
Andres Schanzer, M.D., and Gustavo S. Oderich, M.D.
doi : 10.1056/NEJMcp2108504
N Engl J Med 2021; 385:1690-1698
Lisa Akintilo, M.D., M.P.H., and Alisa Femia, M.D.
doi : 10.1056/NEJMicm2109090
N Engl J Med 2021; 385:1699
Sanjay Woodhull, M.D., and Devan Raja Segar, M.D.
doi : 10.1056/NEJMicm2108193
N Engl J Med 2021; 385:e64
Sook-Bin Woo, D.M.D., M.M.Sc., Markus Y. Wu, M.D., Nathaniel S. Treister, D.M.D., D.M.Sc., Philip C. Amrein, M.D., Daniela Kroshinsky, M.D., M.P.H., and Robert P. Hasserjian, M.D.
doi : 10.1056/NEJMcpc2107352
N Engl J Med 2021; 385:1700-1710
E. Magnus Ohman, M.B.
doi : 10.1056/NEJMe2112747
N Engl J Med 2021; 385:1712-1714
Philip G. Bardin, Ph.D., and Paul S. Foster, D.Sc.
doi : 10.1056/NEJMe2114472
N Engl J Med 2021; 385:1714-1717
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2117187
N Engl J Med 2021; 385:e74
doi : 10.1056/NEJMc2106757
N Engl J Med 2021; 385:1718-1720
doi : 10.1056/NEJMc2111452
N Engl J Med 2021; 385:1720-1721
doi : 10.1056/NEJMc2114592
N Engl J Med 2021; 385:1721-1723
doi : 10.1056/NEJMc2113013
N Engl J Med 2021; 385:1726-1727
doi : 10.1056/NEJMx210014
N Engl J Med 2021; 385:1728
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟